Vital Farms Insider: Option Exercise and 10b5-1 Sales by CFO
Rhea-AI Filing Summary
Vital Farms insider activity: Chief Financial Officer Thilo Wrede exercised employee stock options and sold common shares on 08/14/2025. The CFO exercised options with a $13.91 exercise price to acquire 7,189 shares, and reported ownership of 14,378 derivative shares following the transactions. On the same date, the Reporting Person sold 600 shares at a weighted average price of $47.06 and 2,793 shares at a weighted average price of $47.70 under a Rule 10b5-1 trading plan adopted May 15, 2025. Beneficial ownership reported after the transactions ranged from 62,176 to 58,783 common shares in the table entries.
Positive
- Trades executed under a Rule 10b5-1 plan, indicating a pre-established, documented selling arrangement
- Option exercise disclosed clearly with exercise price of $13.91 and vesting schedule noted
Negative
- Insider sold 3,393 common shares (600 and 2,793) on 08/14/2025, which may be viewed as insider liquidity
- Beneficial ownership decreased in reported table entries from 62,176 to 58,783 common shares after sales
Insights
TL;DR: Insider exercised options at $13.91 and sold shares under a pre-established 10b5-1 plan, signaling routine liquidity rather than an ad-hoc disposition.
The filing shows a simultaneous option exercise (7,189 shares) and planned sales (total 3,393 shares) executed under a Rule 10b5-1 plan adopted May 15, 2025. The exercise price of $13.91 is disclosed and the sales occurred at weighted average prices near $47, indicating a significant spread between strike and sale prices. These are typical director/officer actions to monetize vested equity while relying on an affirmative defense plan. For investors, the activity is informative about insider liquidity but not, by itself, a material change to company operations or financial condition.
TL;DR: Transactions were executed under a documented 10b5-1 plan and include option exercise; governance procedures appear followed.
The Form 4 explicitly checks the box indicating the trades were pursuant to a Rule 10b5-1 plan and includes footnotes committing to provide per-trade price breakdowns. The filing is signed by an attorney-in-fact, showing adherence to procedural requirements. From a governance perspective, the disclosure meets routine transparency expectations for officer transactions; there is no disclosure here of any insider trading concerns beyond planned disposition under the stated plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 7,189 | $0.00 | -- |
| Exercise | Common Stock | 7,189 | $13.91 | $100K |
| Sale | Common Stock | 600 | $47.06 | $28K |
| Sale | Common Stock | 2,793 | $47.70 | $133K |
Footnotes (1)
- These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.45 to $47.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.49 to $48.06 inclusive. The option vests in three equal annual installments commencing on March 17, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
